Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the addition of Sirolimus (rapamycin) to standard
chemotherapy for the treatment of patients with high risk acute myelogenous leukemia (AML).
Cancer cells taken from the patients will be studied in the laboratory to see if rapamycin is
affecting the mTOR pathway in the cells and if this effect is correlated with how well
patients respond to the therapy.
Phase:
N/A
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University